Insurance Coverage, Physician Recommendations, and Access to Emerging Treatments
Open Access
- 4 March 1998
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 279 (9) , 663-668
- https://doi.org/10.1001/jama.279.9.663
Abstract
THE INFLUENCE of insurance on access to health care, especially access to expensive specialist care and treatment, is a major concern.1-3 However, little is known about the spectrum of coverage across insurers or about the agreement between physician recommendations and insurer policies for specific therapies. These concerns are particularly important for emerging and semielective treatments related to quality of life (such as treatments for short stature, infertility, obesity, and aging4), in which consensus about optimal utilization may be lacking.Keywords
This publication has 12 references indexed in Scilit:
- Short stature and growth hormone therapy. A national study of physician recommendation patternsJAMA, 1996
- A Perspective on the Corporate Transformation of Health CareInternational Journal of Health Services, 1995
- Recommendations for Diagnosis, Treatment, and Management of Individuals with Turner SyndromeThe Endocrinologist, 1994
- Life, Death, and the Insurance CompaniesNew England Journal of Medicine, 1994
- Health Insurance and Utilization of Medical Care for Children with Special Health Care NeedsMedical Care, 1993
- Growth Hormone Therapy for Short Stature: Yes or No?Hospital Practice, 1992
- A survey of state medicaid policies for coverage of screening mammography and pap smear servicesWomen's Health Issues, 1992
- Comparison of uninsured and privately insured hospital patients. Condition on admission, resource use, and outcomePublished by American Medical Association (AMA) ,1991
- Clinical longitudinal standards for height and height velocity for North American childrenThe Journal of Pediatrics, 1985
- Prevalence of severe growth hormone deficiency.BMJ, 1977